AnaptysBio, Inc. is a biotechnology company that is spinning out First Tracks Biotherapeutics as a separate, clinical-stage biotech focused on next-generation antibody therapeutics targeting immune pathways in autoimmune and inflammatory diseases. First Tracks Bio’s initial pipeline includes ANB033 for celiac disease and eosinophilic esophagitis, rosnilimab for rheumatoid arthritis, and ANB101, supported by an initial cash balance of $180 million and an expected two-year cash runway.
On March 26–27, 2026, AnaptysBio detailed the planned April 20, 2026 spin-off of First Tracks Bio, including a $80 million private placement that forms part of First Tracks’ $180 million launch capital, a one-for-one share distribution to Anaptys stockholders, and Nasdaq listing under the ticker TRAX. The company also terminated its ATM equity program, appointed Susannah Gray to its board, and set executive transition and separation agreements with Dennis Mulroy and Eric Loumeau as Anaptys refocuses on royalty management while First Tracks drives drug development.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.